Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Biol Blood Marrow Transplant. 2010 Nov;16(11):1541-8. doi: 10.1016/j.bbmt.2010.08.011. Epub 2010 Aug 25.
Allogeneic transplant access can be severely limited for patients of racial and ethnic minorities without suitable sibling donors. Whether cord blood (CB) transplantation can extend transplant access because of the reduced stringency of required HLA-match is not proven. We prospectively evaluated availability of unrelated donors (URD) and CB according to patient ancestry in 553 patients without suitable sibling donors. URDs had priority if adequate donors were available. Otherwise ≥4/6 HLA-matched CB grafts were chosen utilizing double units to augment graft dose. Patients had highly diverse ancestries including 35% non-Europeans. In 525 patients undergoing combined searches, 10/10 HLA-matched URDs were identified in 53% of those with European ancestry, but only 21% of patients with non-European origins (P < .001). However, the majority of both groups had 5-6/6 CB units. The 269 URD transplant recipients were predominantly European, with non-European patients accounting for only 23%. By contrast, 56% of CB transplant recipients had non-European ancestries (P < .001). Of 26 patients without any suitable stem cell source, 73% had non-European ancestries (P < .001). Their median weight was significantly higher than CB transplant recipients (P <.001), partially accounting for their lack of a CB graft. Availability of CB significantly extends allo-transplant access, especially in non-European patients, and has the greatest potential to provide a suitable stem cell source regardless of race or ethnicity. Minority patients in need of allografts, but without suitable matched sibling donors, should be referred for combined URD and CB searches to optimize transplant access.
对于没有合适同胞供体的少数族裔和种族患者,同种异体移植的途径可能受到严重限制。脐带血 (CB) 移植是否可以通过降低所需 HLA 匹配的严格程度来扩大移植途径尚不清楚。我们前瞻性地评估了 553 名无合适同胞供体患者的患者种族与无关供体 (URD) 和 CB 的可用性。如果有足够的供体,URD 优先。否则,选择≥4/6 HLA 匹配的 CB 移植物,利用双单位增加移植物剂量。患者的祖源具有高度多样性,包括 35%的非欧洲人。在 525 名接受联合搜索的患者中,在具有欧洲血统的患者中,有 53%的患者确定了 10/10 HLA 匹配的 URD,而非欧洲起源的患者只有 21%(P<.001)。然而,两组患者的大多数都有 5-6/6 CB 单位。269 名 URD 移植受者主要是欧洲人,只有 23%是非欧洲人。相比之下,56%的 CB 移植受者有非欧洲血统(P<.001)。在 26 名没有任何合适干细胞来源的患者中,73%有非欧洲血统(P<.001)。他们的中位体重明显高于 CB 移植受者(P<.001),这在一定程度上解释了他们没有 CB 移植物的原因。CB 的可用性显著扩大了同种异体移植的途径,特别是在非欧洲患者中,并且无论种族或民族如何,都有最大的潜力提供合适的干细胞来源。需要同种异体移植但没有合适同胞供体的少数民族患者应被转介进行 URD 和 CB 联合搜索,以优化移植途径。